Update on Crestor

AstraZeneca PLC
06 August 2002







ASTRAZENECA UPDATE ON CRESTOR



Following a constructive meeting with the US Food and Drug Administration (FDA)
to discuss the company's response to the approvable letter for Crestor
(rosuvastatin calcium), AstraZeneca has undertaken to provide further
information from its ongoing study programme to supplement that already
submitted.



This response to the approvable letter will support the use of Crestor over the
dose range of 10-40mg in the general population of patients with lipid disorders
and is scheduled for submission during the first quarter 2003.



There are now more than 10,000 patients in on-going studies of Crestor and the
company remains confident in the product's profile and commercial potential.



The company's guidance on earnings for 2002 remains unchanged.





                                    - Ends -

August 6, 2002



Media Enquiries:

Chris Major, Tel: [phone]
Steve Brown, Tel: [phone]



Investor Relations:

Mina Blair Robinson, Tel: [phone]
Jonathan Hunt, Tel: [phone]
Jorgen Winroth, Tel: [phone]




                      This information is provided by RNS
            The company news service from the London Stock Exchange
    

RAPBKAKKNBKDOFK